Correlation Between Sellas Life and Protalix Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Sellas Life and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sellas Life and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sellas Life Sciences and Protalix Biotherapeutics, you can compare the effects of market volatilities on Sellas Life and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sellas Life with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sellas Life and Protalix Biotherapeutics.

Diversification Opportunities for Sellas Life and Protalix Biotherapeutics

-0.18

Correlation Coefficient

Sellas Life  Protalix Biotherapeutics

Good diversification

The 3 months correlation between Sellas and Protalix is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Sellas Life Sciences and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Sellas Life is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sellas Life Sciences are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Sellas Life i.e., Sellas Life and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Sellas Life and Protalix Biotherapeutics

Considering the 90-day investment horizon Sellas Life Sciences is expected to under-perform the Protalix Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sellas Life Sciences is 1.07 times less risky than Protalix Biotherapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Protalix Biotherapeutics is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  112.00  in Protalix Biotherapeutics on September 5, 2024 and sell it today you would earn a total of  52.00  from holding Protalix Biotherapeutics or generate 46.43% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Sellas Life Sciences  vs.  Protalix Biotherapeutics

Sellas Life Sciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sellas Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Sellas Life is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Protalix Biotherapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Sellas Life and Protalix Biotherapeutics

The main advantage of trading using opposite Sellas Life and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sellas Life position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.

The idea behind Sellas Life Sciences and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.